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BACKGROUND
In two interim analyses of this trial, patients with advanced heart failure who were 
treated with a fully magnetically levitated centrifugal-flow left ventricular assist 
device were less likely to have pump thrombosis or nondisabling stroke than were 
patients treated with a mechanical-bearing axial-flow left ventricular assist device.
METHODS
We randomly assigned patients with advanced heart failure to receive either the 
centrifugal-flow pump or the axial-flow pump irrespective of the intended goal of 
use (bridge to transplantation or destination therapy). The composite primary end 
point was survival at 2 years free of disabling stroke or reoperation to replace or 
remove a malfunctioning device. The principal secondary end point was pump 
replacement at 2 years.
RESULTS
This final analysis included 1028 enrolled patients: 516 in the centrifugal-flow 
pump group and 512 in the axial-f low pump group. In the analysis of the pri-
mary end point, 397 patients (76.9%) in the centrifugal-f low pump group, as 
compared with 332 (64.8%) in the axial-flow pump group, remained alive and free 
of disabling stroke or reoperation to replace or remove a malfunctioning device at 
2 years (relative risk, 0.84; 95% confidence interval [CI], 0.78 to 0.91; P<0.001 for 
superiority). Pump replacement was less common in the centrifugal-flow pump 
group than in the axial-f low pump group (12 patients [2.3%] vs. 57 patients 
[11.3%]; relative risk, 0.21; 95% CI, 0.11 to 0.38; P<0.001). The numbers of events 
per patient-year for stroke of any severity, major bleeding, and gastrointestinal 
hemorrhage were lower in the centrifugal-flow pump group than in the axial-flow 
pump group.
CONCLUSIONS
Among patients with advanced heart failure, a fully magnetically levitated centrifugal-
flow left ventricular assist device was associated with less frequent need for pump 
replacement than an axial-flow device and was superior with respect to survival 
free of disabling stroke or reoperation to replace or remove a malfunctioning device. 
(Funded by Abbott; MOMENTUM 3 ClinicalTrials.gov number, NCT02224755.)
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The use of left ventricular assist devices in patients with advanced-stage heart failure is beleaguered by hemocom-
patibility-related complications of thrombosis, 
stroke, and bleeding, which are consequences of 
adverse interactions between the pump and circu-
lating blood elements.1 Advances in bioengineer-
ing have led to the introduction of durable con-
tinuous-flow left ventricular assist devices, but 
concerns have been raised about the risk of pump 
thrombosis causing device malfunction.2 The shear 
stress created by continuous-flow pumps also 
leads to degradation of high-molecular-weight 
multimers of von Willebrand factor, a phenom-
enon that has been implicated in the development 
of mucosal arteriovenous malformations and 
bleeding.3,4 In addition, a high frequency of stroke 
remains a serious concern for patients who re-
ceive a left ventricular assist device.5
The most widely implanted left ventricular as-
sist device, the Heartmate II (Abbott), is an axial 
continuous-flow pump, which requires thoraco-
abdominal placement.6 An intrapericardial centrif-
ugal-flow pump, the HVAD (Medtronic), was found 
to be noninferior to the HeartMate II device with 
regard to survival but was associated with a higher 
incidence of stroke.7 A fully magnetically levitated 
centrifugal-flow intrathoracic left ventricular as-
sist device, the HeartMate 3 (Abbott), has been 
engineered with wide blood-flow pathways, fric-
tion-free movement, and intrinsic pulsatility to 
reduce shear stress and stasis of blood.8
In the Multicenter Study of MagLev Technology 
in Patients Undergoing Mechanical Circulatory 
Support Therapy with HeartMate 3 (MOMENTUM 
3), the HeartMate 3 centrifugal-flow left ventricu-
lar assist device was compared with the HeartMate 
II axial-flow device, either as a bridge to transplan-
tation or as destination therapy, in 1028 patients 
with advanced-stage heart failure.9 We previ-
ously reported prespecified 6-month and 2-year 
interim outcomes in smaller trial cohorts from 
MOMENTUM 3 (294 and 366 patients, respective-
ly).9-11 These analyses showed a lower incidence of 
pump thrombosis leading to malfunction with the 
centrifugal-flow pump than with the axial-flow 
device. The 2-year interim analysis also suggested 
a lower incidence of nondisabling stroke with the 
centrifugal-flow pump.11 We now provide the fi-
nal report of efficacy and safety end points in the 
full trial population (Fig. S1 in the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org).
Me thods
Trial Design
In this randomized trial, we compared a centrifu-
gal-f low left ventricular assist device with an 
axial-flow device in patients with advanced-stage 
heart failure. Details of the trial design have 
been published previously.9-11 The protocol was 
approved by each institutional review board at 
69 participating centers in the United States. The 
trial was sponsored by Abbott, which provided 
the devices, selected the sites, and analyzed the 
data (as indicated in the Supplementary Appendix), 
with verification performed by an independent 
statistician. The authors vouch for the complete-
ness and accuracy of all the data and analyses 
and for fidelity of the trial to the protocol, which 
is available at NEJM.org.
Trial Population
We enrolled patients with advanced-stage heart 
failure who were deemed to be candidates for 
therapy with a left ventricular assist device, irre-
spective of whether the intended goal was to pro-
vide support as a bridge to transplantation or as 
destination therapy. Patients were excluded from 
the trial if biventricular circulatory support was 
expected to be necessary or if irreversible end-
organ dysfunction or active infection was pres-
ent. Written informed consent was obtained from 
all patients or their authorized representatives. 
Detailed inclusion and exclusion criteria are pro-
vided in the Supplementary Appendix.
Randomization and Data Collection
Patients were randomly assigned in a 1:1 ratio to 
receive either the centrifugal-flow pump or the 
axial-flow pump. Randomization was performed 
with the use of permuted blocks and stratification 
according to study center and was implemented 
with the use of an electronic data-capture system 
(eClinicalOS, Merge Healthcare). The investigators 
and patients were aware of the treatment assign-
ments. Data on end points and adverse events 
were collected after implantation at 1 day, 1 week, 
discharge, 1 month, 3 months, 6 months, and then 
every 6 months until 2 years of follow-up had 
been completed.
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Left Ventricular Assist Systems
The two left ventricular assist devices used were 
the HeartMate 3 fully magnetically levitated cen-
trifugal continuous-flow pump and the Heart-
Mate II mechanical-bearing axial continuous-flow 
pump. All the investigators were experienced in 
the use of the control axial-flow pump and un-
derwent training before their first implantation 
of a centrifugal-flow pump. The recommended 
antithrombotic treatment in each group included 
aspirin at a dose of 81 to 325 mg daily and warfa-
rin (target range for the international normalized 
ratio, 2.0 to 3.0).
End Points
The composite primary end point was survival at 
2 years free of disabling stroke or reoperation to 
replace or remove a malfunctioning device. In 
the analysis of the primary end point, disabling 
stroke was defined by a modified Rankin score 
of greater than 3 (scores range from 0 to 6, with 
higher scores indicating greater disability). The 
principal secondary end point, which the trial was 
separately powered to assess, was pump replace-
ment at 2 years after implantation. Other second-
ary end points included actuarial survival, rehos-
pitalization, functional status, and quality of life. 
Subgroup analyses were prespecified for age, sex, 
race, intended goal of therapy (bridge to transplan-
tation or destination therapy), and severity of ill-
ness at baseline.
The rates of major adverse events such as 
stroke, bleeding, right heart failure, and infection 
were also evaluated (definitions are provided in the 
Supplementary Appendix). An independent clin-
ical-events committee, the members of which were 
unaware of the treatment assignments, adjudi-
cated the causes of death and bleeding, infection, 
neurologic dysfunction, suspected device throm-
bosis, and hemolysis. A 6-minute walk test ad-
ministered by a trained technician and New York 
Heart Association (NYHA) classification were used 
to evaluate functional status. Quality of life was 
assessed with the European Quality of Life–5 Di-
mensions (EQ-5D) 5-Level questionnaire (EQ-5D-
5L), the EQ-5D visual-analogue scale (EQ-5D VAS), 
and the Kansas City Cardiomyopathy Question-
naire (KCCQ).
Statistical Analysis
The sample size for the full cohort of patients who 
underwent randomization was calculated to test 
whether the centrifugal-flow left ventricular as-
sist device was superior to the axial-flow left ven-
tricular assist device with respect to the percent-
age of patients undergoing pump replacement at 
2 years. We determined that, with 7% of patients 
in the axial-flow pump group and 3% of patients 
in the centrifugal-flow pump group expected to 
have undergone pump replacement at 2 years, 
1028 patients would be required to show superi-
ority with a power of 80% and an alpha of 0.05 
(two-sided) (details are provided in the Supple-
mentary Appendix).
The primary end point was analyzed in the 
intention-to-treat population, which included all 
patients who underwent randomization. Patients 
were considered to have had treatment failure with 
respect to the primary end point if any of the fol-
lowing events occurred: withdrawal from the trial 
before implantation (i.e., the patient underwent 
randomization but did not undergo implantation 
of the assigned device), withdrawal from the trial 
after implantation, death, disabling stroke, any 
pump replacement, urgent transplantation for de-
vice malfunction, or pump explantation or perma-
nent deactivation for a reason other than myocar-
dial recovery. If a patient had more than one of 
these events, the event that occurred first was 
noted as the treatment-failure event in the analysis 
of the primary end point. Transplantation for rea-
sons other than device malfunction and pump 
explantation or permanent deactivation for myo-
cardial recovery were not considered treatment-
failure events.
Noninferiority with regard to the primary end 
point would be shown if the lower 95% confidence 
boundary of the difference between the treatment 
groups (centrifugal-flow pump minus axial-flow 
pump) in the percentage of patients remaining 
alive and free of disabling stroke or reoperation 
to replace or remove a malfunctioning device at 
2 years was numerically greater than −10 percent-
age points (i.e., closer to or greater than zero) 
with a two-tailed P value of less than 0.05, cal-
culated by the Farrington–Manning risk-differ-
ence approach. If noninferiority was met, then 
superiority was evaluated with the z test of pro-
portions, with the use of the normal approxima-
tion to the binomial distribution. Relative risks 
and 95% confidence intervals for the primary 
end point and its component events are shown, 
and actuarial event-free survival was calculated 
by the Kaplan–Meier method.
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All secondary end points were analyzed in the 
per-protocol population, which included all pa-
tients who underwent randomization and received 
the assigned device. The principal secondary end 
point was analyzed with Fisher’s exact test. Pois-
son regression was used to compare the rates of 
major adverse events between the two treatment 
groups as numbers of events per patient-year. 
The rate differences are described as relative risks 
with the corresponding 95% confidence intervals. 
The incidence of rehospitalization in discharged 
patients was evaluated with the Andersen–Gill 
model. Overall survival was analyzed by the Ka-
plan–Meier method, with data censored for non-
fatal outcomes, such as transplantation. Hazard 
ratios were calculated from Cox proportional-
hazards models. Longitudinal changes in func-
tional status and quality of life were analyzed by 
means of linear mixed-effects modeling.
The reported P values for the primary and prin-
cipal secondary end point are two-tailed. The 95% 
confidence intervals have not been adjusted for 
multiplicity, and therefore inferences drawn from 
these intervals may not be reproducible. Statisti-
cal analyses were performed with the use of SAS 
software, version 9.4 or higher (SAS Institute).
R esult s
Patients and Device Implantation
From September 2014 through August 2016, a 
total of 1028 patients underwent randomization 
(516 patients to the centrifugal-flow pump group 
and 512 patients to the axial-flow pump group) 
(Fig. S2 in the Supplementary Appendix). The base-
line characteristics of the patients are shown in 
Table 1, and in Table S1 in the Supplementary 
Appendix.
One patient who had been assigned to receive 
the centrifugal-flow pump and 7 who had been 
assigned to receive the axial-flow pump did not 
undergo implantation per protocol. The remain-
ing patients (per-protocol population) included 
515 who underwent implantation of a centrifugal-
flow pump and 505 who underwent implanta-
tion of an axial-flow pump. A total of 126 surgeons 
performed 1020 implantations at 69 sites.
End Points
All patients were followed for 2 years, and no end-
point data were missing. In the analysis of the 
primary end point, a larger percentage of patients 
in the centrifugal-flow pump group than in the 
axial-flow pump group remained alive and free 
of disabling stroke or reoperation to replace or 
remove a malfunctioning device at 2 years (397 
patients [76.9%] vs. 332 patients [64.8%]). The 
noninferiority criterion (absolute between-group 
difference, 12.1 percentage points; 95% confidence 
interval [CI], 6.0 to 18.2; P<0.001) and superiority 
criterion (relative risk, 0.84; 95% CI, 0.78 to 0.91; 
P<0.001) were met. Details of the primary end-
point components according to the first treat-
ment-failure event that occurred are shown in 
Table 2, and in Table S2 in the Supplementary 
Appendix.
In a worst-case sensitivity analysis, patients in 
the axial-flow pump group who withdrew from 
the trial before or after implantation or who un-
derwent urgent heart transplantation for device 
malfunction were considered to have had treat-
ment success, whereas such patients in the cen-
trifugal-flow pump group were still considered to 
have had treatment failure (Table S3 in the Sup-
plementary Appendix). The result of this analysis 
was similar to that of the primary end-point analy-
sis (relative risk, 0.91; 95% CI, 0.84 to 0.98). The 
Kaplan–Meier estimates of actuarial event-free 
survival at 2 years (primary end point) in the inten-
tion-to-treat population were 74.7% in the centrifu-
gal-flow pump group and 60.6% in the axial-flow 
pump group (Fig. 1).
The principal secondary end point of pump 
replacement at 2 years occurred less frequently in 
the centrifugal-flow pump group than in the 
axial-f low pump group (12 patients [2.3%] vs. 
57 patients [11.3%]; relative risk, 0.21; 95% CI, 
0.11 to 0.38; P<0.001) (Table 2). A list of the spe-
cific reasons for pump replacement in each group 
is provided in Table S4 in the Supplementary 
Appendix.
Clinical Course
Discharge from the hospital with the device in 
place occurred in 485 of 515 patients (94.2%) in 
the centrifugal-flow pump group and 471 of 505 
(93.3%) in the axial-flow pump group. The median 
length of stay during the hospitalization for im-
plantation was 19 days in the centrifugal-flow 
pump group and 17 days in the axial-flow pump 
group. The median number of days of rehospital-
ization, days spent outside the hospital receiving 
left ventricular assist device support, and all-cause 
rehospitalization rates are shown in Table 3.
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Characteristic
Centrifugal-Flow Pump Group 
(N = 516)
Axial-Flow Pump Group 
(N = 512)
Age — yr
Mean 59±12 60±12
Median (range) 62 (18–83) 63 (21–84)
Male sex — no. (%) 411 (79.7) 419 (81.8)
Race or ethnic group — no. (%)†
White 342 (66.3) 367 (71.7)
Black 145 (28.1) 120 (23.4)
Asian 8 (1.6) 3 (0.6)
Native Hawaiian or Pacific Islander 0 4 (0.8)
Other 21 (4.1) 18 (3.5)
Body-surface area — m2 2.1±0.3 2.1±0.3
Ischemic cause of heart failure — no. (%) 216 (41.9) 240 (46.9)
History of atrial fibrillation — no. (%) 215 (41.7) 238 (46.5)
History of stroke — no. (%) 50 (9.7) 56 (10.9)
Previous cardiac surgical procedures — no. (%)
Coronary-artery bypass 102 (19.8) 114 (22.3)
Valve replacement or repair 36 (7.0) 31 (6.1)
Left ventricular ejection fraction — % 17.3±5.1 17.2±5.0
Arterial blood pressure — mm Hg
Systolic 108.4±14.7 106.5±14.5
Diastolic 66.8±10.6 65.7±10.2
Mean arterial pressure — mm Hg 79.2±10.4 79.2±10.1
Pulmonary-capillary wedge pressure — mm Hg 23.1±8.6 22.9±9.2
Cardiac index — liters/min/m2 2.0±0.5 2.0±0.6
Pulmonary vascular resistance — Wood units 3.1±1.7 3.0±1.7
Right atrial pressure — mm Hg 10.8±6.5 10.7±6.8
Serum sodium level — mmol/liter 135.4±4.1 135.5±4.2
Serum creatinine level — mg/dl 1.4±0.4 1.4±0.4
Estimated glomerular filtration rate — ml/min/1.73 m2 61.3±23.7 59.5±22.0
Intended goal of pump support — no. (%)
Bridge to transplantation 113 (21.9) 121 (23.6)
Bridge to candidacy for transplantation 86 (16.7) 81 (15.8)
Destination therapy 317 (61.4) 310 (60.5)
*  Plus–minus values are means ±SD. There were no significant differences between the groups in any characteristic ex-
cept for race (P = 0.04) and systolic blood pressure (P = 0.03). The intention-to-treat population included all patients 
who underwent randomization. Data on Interagency Registry for Mechanically Assisted Circulatory Support 
(INTERMACS) profiles and concomitant medications and cardiac interventions are provided in Table S1 in the 
Supplementary Appendix. Percentages may not total 100 because of rounding. To convert the serum creatinine level to 
micromoles per liter, multiply by 88.4.
†  Race or ethnic group was reported by the patient.
Table 1. Baseline Characteristics of Patients in the Intention-to-Treat Population.*
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There were 98 deaths in the centrifugal-flow 
pump group and 103 in the axial-flow pump group 
after implantation, with no significant difference 
in overall survival between the groups (Fig. S3 in 
the Supplementary Appendix). The most common 
causes of death among the patients with either 
device were right heart failure, stroke, and infec-
tion (Table S5 in the Supplementary Appendix). 
Competing-risk curves that reflect the cumulative 
percentages of patients in each group who had an 
outcome of ongoing device support, transplanta-
tion, device explantation or deactivation, or death 
through 2 years are shown in Figure S4 in the 
Supplementary Appendix.
Safety Outcomes
Between-group comparisons of event rates for 
hemocompatibility-related adverse events (includ-
ing pump thrombosis, stroke, and bleeding) and 
other major events are shown in Figure 2. Instan-
taneous hazard risk curves are shown in Figure S5 
in the Supplementary Appendix. There were 70 
cases of suspected or confirmed pump thrombo-
sis with the axial-flow pump and 7 cases with the 
centrifugal-flow pump; narratives of these events 
with the centrifugal-flow pump are provided in the 
Supplementary Appendix. Data on other major 
adverse events are shown in Figure S6 and Ta-
bles S6 and S7 in the Supplementary Appendix. 
Ventricular arrhythmias were less frequent with 
the centrifugal-flow pump than with the axial-
flow device.
There were no significant differences between 
the groups with respect to clinical factors asso-
ciated with stroke risk, including history of atrial 
fibrillation, history of stroke, maintenance of mean 
arterial blood pressure at or below 90 mm Hg, or 
receipt of antithrombotic therapy during the trial. 
Lactate dehydrogenase levels were lower in the 
centrifugal-flow pump group than in the axial-
flow pump group. Details of these analyses and 
data regarding hepatic and renal function are pro-
vided in Table 1, and in Tables S8 through S10 and 
Figure S7 in the Supplementary Appendix.
Figure 1. Kaplan–Meier Estimates of the Primary End Point in the Intention-
to-Treat Population.
The intention-to-treat population included all patients who underwent ran-
domization. The primary end point was a composite of survival free of dis-
abling stroke or reoperation to replace or remove a malfunctioning device 
at 24 months after implantation. Disabling stroke was defined by a modi-
fied Rankin score of greater than 3 (scores range from 0 to 6, with higher 
scores indicating more severe disability). Kaplan–Meier estimates for the 
primary end point at 6, 12, and 24 months are shown. The 95% confidence 
intervals have not been adjusted for multiplicity, and therefore inferences 
drawn from these intervals may not be reproducible.
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End Point
Centrifugal-Flow 
 Pump Group 
(N = 485)
Axial-Flow 
 Pump Group 
(N = 471)
Difference or 
 Hazard Ratio (95% CI)
Median duration of rehospitalization (interquartile range) — days 13 (4 to 37) 18 (6 to 40) −5 (−8.7 to −1.3)
Median duration receiving left ventricular assist device support 
outside hospital (interquartile range) — days
653 (333 to 696) 605 (259 to 690) 48 (−0.8 to 96.8)
Rate of rehospitalization for any cause — events per patient-yr 2.26 2.47 0.92 (0.86 to 0.99)†
*  The per-protocol population included all patients who underwent randomization and received the assigned device. The 95% confidence in-
tervals have not been adjusted for multiplicity, and therefore inferences drawn from these intervals may not be reproducible.
†  The hazard ratio was derived from the Andersen–Gill model for the comparison of all-cause readmissions between the groups.
Table 3. Postdischarge End Points among Patients Discharged while Receiving Left Ventricular Assist Device Support (Per-Protocol 
Population).*
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Functional Status and Quality of Life
For both groups, there were sustained improve-
ments from baseline in the 6-minute walk test, 
NYHA functional class, KCCQ overall summary 
score, EQ-5D-5L total score, and the EQ-5D VAS 
(Fig. S8 in the Supplementary Appendix). There 
were no significant differences in functional-status 
test results or quality-of-life measures between the 
treatment groups. Sensitivity analyses accounting 
for missing values favored the centrifugal-flow 
pump group over the axial-f low pump group 
with regard to the NYHA classification and the 
EQ-5D VAS.
Subgroup Analyses
No interaction between the groups was observed 
for the prespecified subgroups of age, sex, race 
or ethnic group, intended goal of pump support 
(bridge to transplantation or destination ther-
apy), or Interagency Registry for Mechanically 
Assisted Circulatory Support (INTERMACS) pro-
file with regard to the primary end point. De-
tails are provided in Figure S9 in the Supple-
mentary Appendix.
Discussion
In this final report of the MOMENTUM 3 trial, 
we showed that the HeartMate 3 fully magneti-
cally levitated centrifugal-flow pump was superior 
to the HeartMate II axial-flow left ventricular as-
sist system with respect to survival free of dis-
abling stroke or reoperation to replace or remove 
a malfunctioning device. In addition to reducing 
the need for pump replacement (mostly for pump 
thrombosis), the centrifugal-flow pump was as-
sociated with a lower incidence of either ischemic 
or hemorrhagic strokes of any severity and fewer 
bleeding events. We calculate that for every 10 pa-
tients who received the centrifugal-f low pump 
rather than the axial-flow pump, 2.2 pump-throm-
bosis events, 2 strokes, and 6.8 bleeding events 
(3.6 gastrointestinal bleeds) were averted over a 
2-year period. These findings were accompanied 
Figure 2. Principal Safety Outcomes in the Per-Protocol Population.
Relative risks of key adverse events, calculated on the basis of the number of events per patient-year in the centrifugal-flow pump group 
as compared with the axial-flow pump group, are shown. The per-protocol population included all patients who underwent randomization 
and received the assigned device. The relative risk of an adverse event favors the centrifugal-flow pump when the upper boundary of  
the 95% confidence interval is less than 1.0. Neither pump is favored when the 95% confidence interval spans the line of unity. The 95% 
confidence intervals have not been adjusted for multiplicity, and therefore inferences drawn from these intervals may not be reproduc-
ible. Narratives for suspected pump-thrombosis events in the centrifugal-flow pump group are provided in the Supplementary Appen-
dix. P values for relative risk are derived from Poisson regression. Other neurologic events included transient ischemic attack, seizure, 
encephalopathy, and neurologic events other than stroke.
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by fewer days spent in the hospital at 2 years 
among patients who received the magnetically 
levitated left ventricular assist device.
Reports of lower stroke rates with the centrifu-
gal pump that were noted in earlier analyses of 
this trial were interpreted cautiously, since only 
the rates of nondisabling strokes were favorably 
influenced.11-14 In the population in the current 
analysis, which was 3 times as large, we found 
lower rates of both hemorrhagic and ischemic 
strokes and a lower rate of disabling strokes. 
Stroke rates were not influenced by differences 
in baseline rates of atrial fibrillation, anticoagu-
lation regimens, or blood pressure control in our 
current or previous analyses.14
The magnetically levitated centrifugal pump 
does not degrade high-molecular-weight multi-
mers of Von Willebrand factor to the extent ob-
served with other devices.15 This finding is con-
sistent with the lower lactate dehydrogenase levels 
that were found in patients with this pump, which 
suggests that less hemolysis was occurring. How-
ever, in previous analyses of the MOMENTUM 3 
trial, no discernible benefit with regard to the 
incidence of mucosal bleeding was noted.10,11 In 
this final analysis involving the full trial popula-
tion, we noted that the centrifugal pump was as-
sociated with lower rates of bleeding, including 
gastrointestinal bleeding, which is linked with the 
unique physiological features of continuous-flow 
left ventricular assist devices.16,17 However, a sig-
nificant residual risk of bleeding persists, which 
suggests the need to investigate whether a re-
duction in the exposure of patients with these 
pumps to antiplatelet or anticoagulation therapy 
would be beneficial.2,18
In our trial, infections affecting the drive line 
exit site and in other locations occurred frequent-
ly, with no significant differences between left 
ventricular assist devices. Studies have made note 
of aberrant T-cell activation and compromised cel-
lular immunity in patients with older pumps.19,20 
Efforts to eliminate the drive line by developing 
internally powered durable heart pumps are likely 
to be an important advance in this regard. How-
ever, vigilance in preventing generalized infections 
will remain important.21,22 Late-onset right heart 
failure, a leading cause of death, also needs fur-
ther study.23,24 Outflow-graft twist occlusion, a 
unique adverse event with the centrifugal pump, 
has been noted previously.25-27 Recognition of this 
insidious complication is important, since it com-
promises pump flow and may mimic pump 
thrombosis. A surgical clip to fix the pump out-
flow graft to the connector is now available to 
help prevent outflow-graft rotation.
In summary, in this final analysis from the 
MOMENTUM 3 trial, the centrifugal-flow Heart-
Mate 3 left ventricular assist device was associated 
with a less frequent need for pump replacement 
than the axial-flow HeartMate II left ventricular 
assist device and was superior to the axial-flow 
pump with respect to survival free of disabling 
stroke or reoperation to replace or remove a mal-
functioning device.
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